Department of Psychiatry and Behavioral Neuroscience, University of Chicago, Chicago, Illinois, USA.
Int Clin Psychopharmacol. 2022 Jan 1;37(1):14-20. doi: 10.1097/YIC.0000000000000382.
Body-focused repetitive behaviors (BFRBs) such as trichotillomania and skin picking disorder are associated with decreased self-esteem and poor quality of life. The objective of this study was to evaluate dronabinol, a cannabinoid agonist, for the reduction of BFRB symptoms. Fifty adults with either trichotillomania (n = 34) or skin picking disorder (n = 16) were recruited for a randomized, double-blind, placebo-controlled study. Participants received 10-week treatment with dronabinol (5-15 mg/day) or placebo. The primary efficacy outcome measure was the change on the clinician-rated National Institute of Mental Health scale for hair pulling or skin picking. Both dronabinol and placebo treatment were associated with significant reductions in BFRB symptoms. Dronabinol did not significantly separate from placebo on any efficacy measure. At week 10, 67% of the treatment group were classified as responders (Clinical Global Impressions-Improvement Score of very much or much improved) compared to 50% in the placebo group (P value = 0.459). This study assessed the efficacy of dronabinol, a synthetic form of tetrahydrocannabinol, in the treatment of BFRBs, and found no differences in symptom reductions between dronabinol and placebo.
躯体聚焦性重复行为（BFRBs），如拔毛癖和皮肤搔抓障碍，与自尊心下降和生活质量差有关。本研究旨在评估大麻素激动剂大麻隆（dronabinol）对减少 BFRB 症状的作用。50 名患有拔毛癖（n=34）或皮肤搔抓障碍（n=16）的成年人被招募参加一项随机、双盲、安慰剂对照研究。参与者接受为期 10 周的大麻隆（5-15mg/天）或安慰剂治疗。主要疗效评估指标为临床医生评定的毛发牵拉或皮肤搔抓的国家心理健康研究所量表的变化。大麻隆和安慰剂治疗均与 BFRB 症状的显著减轻相关。大麻隆在任何疗效指标上均未与安慰剂显著分离。在第 10 周时，治疗组中有 67%的患者被归类为应答者（临床总体印象-改善评分非常或明显改善），而安慰剂组为 50%（P 值=0.459）。本研究评估了合成形式的四氢大麻酚大麻隆治疗 BFRBs 的疗效，未发现大麻隆与安慰剂在症状减轻方面的差异。
